Genetic Technologies Limited – NASDAQ:GENE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Genetic Technologies Limited stock price monthly change
-3.75%
month
Genetic Technologies Limited stock price quarterly change
-3.75%
quarter
Genetic Technologies Limited stock price yearly change
+35.09%
year
Genetic Technologies Limited key metrics
Market Cap | 3.70M |
Enterprise value | 13.40M |
P/E | -2.71 |
EV/Sales | 1042.98 |
EV/EBITDA | -3.91 |
Price/Sales | 1831.84 |
Price/Book | 2.13 |
PEG ratio | -0.02 |
EPS | -0.14 |
Revenue | 14.84M |
EBITDA | -12.46M |
Income | -14.31M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -26936.02% |
Oper. margin | -31908.35% |
Gross margin | -833.48% |
EBIT margin | -31908.35% |
EBITDA margin | -84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGenetic Technologies Limited stock price history
Genetic Technologies Limited stock forecast
Genetic Technologies Limited financial statements
| Mar 2022 | 2.88M | -1.62M | -56.38% |
|---|---|---|---|
| Jun 2022 | 4.74M | -3.24M | -68.5% |
| Mar 2023 | 2.68M | -3.14M | -117.14% |
| Jun 2023 | 4.53M | -6.29M | -138.8% |
| 2026 | 18.23M | 0 |
|---|
Analysts Price target
Financials & Ratios estimates
| Nov 2022 | 15694649 | 4.66M | 29.73% |
|---|---|---|---|
| Dec 2022 | 15694649 | 4.66M | 29.73% |
| Apr 2023 | 14856237 | 3.69M | 24.86% |
| Jun 2023 | 14856237 | 3.69M | 24.86% |
| Jun 2022 | -1.49M | 27.83K | -263.61K |
|---|---|---|---|
| Mar 2023 | -1.02M | -1K | 6.32M |
| Jun 2023 | -2.62M | -12K | -63.66K |
| Mar 2024 | 0 | -1K | 601K |
Genetic Technologies Limited alternative data
| Aug 2023 | 52 |
|---|---|
| Sep 2023 | 52 |
| Oct 2023 | 52 |
| Nov 2023 | 52 |
| Dec 2023 | 60 |
| Jan 2024 | 60 |
| Feb 2024 | 60 |
| Mar 2024 | 60 |
| Apr 2024 | 60 |
| May 2024 | 60 |
| Jun 2024 | 60 |
| Jul 2024 | 60 |
Genetic Technologies Limited other data
0.00%
-0.00%
of GENE is owned by hedge funds
42.12K
-177.65K
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 8 Feb 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 15 Nov 2017 Issue date: 27 Jul 2021 |
Grant Filling date: 31 May 2016 Issue date: 8 Jun 2021 |
Grant Filling date: 29 Sep 2015 Issue date: 16 Feb 2021 |
Application Filling date: 12 Oct 2018 Issue date: 12 Nov 2020 |
Grant Filling date: 19 Apr 2016 Issue date: 16 Jun 2020 |
Application Filling date: 23 Jan 2018 Issue date: 2 Apr 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2023 9 Aug 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 May 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Feb 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 6 Nov 2022 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD (1967) Chief Financial Officer & Company Sec. | $207,600 |
Dr. Richard Allman (1960) Chief Scientific Officer | $146,190 |
Mr. Stanley Sack (1964) Chief Operating Officer | $103,080 |
-
When is Genetic Technologies Limited's next earnings date?
Unfortunately, Genetic Technologies Limited's (GENE) next earnings date is currently unknown.
-
Does Genetic Technologies Limited pay dividends?
No, Genetic Technologies Limited does not pay dividends.
-
How much money does Genetic Technologies Limited make?
Genetic Technologies Limited has a market capitalization of 3.70M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 25.93% to 7.66M US dollars.
-
What is Genetic Technologies Limited's stock symbol?
Genetic Technologies Limited is traded on the NASDAQ under the ticker symbol "GENE".
-
What is Genetic Technologies Limited's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Genetic Technologies Limited?
Shares of Genetic Technologies Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Genetic Technologies Limited's key executives?
Genetic Technologies Limited's management team includes the following people:
- Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer & Company Sec.(age: 58, pay: $207,600)
- Dr. Richard Allman Chief Scientific Officer(age: 65, pay: $146,190)
- Mr. Stanley Sack Chief Operating Officer(age: 61, pay: $103,080)
-
How many employees does Genetic Technologies Limited have?
As Jul 2024, Genetic Technologies Limited employs 60 workers.
-
When Genetic Technologies Limited went public?
Genetic Technologies Limited is publicly traded company for more then 20 years since IPO on 6 Sep 2005.
-
What is Genetic Technologies Limited's official website?
The official website for Genetic Technologies Limited is gtglabs.com.
-
Where are Genetic Technologies Limited's headquarters?
Genetic Technologies Limited is headquartered at 60-66 Hanover Street, Fitzroy, VIC.
-
How can i contact Genetic Technologies Limited?
Genetic Technologies Limited's mailing address is 60-66 Hanover Street, Fitzroy, VIC and company can be reached via phone at +61 3 8412 7000.
Genetic Technologies Limited company profile:
Genetic Technologies Limited
gtglabs.comExchange:
NASDAQ
Full time employees:
55
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
60-66 Hanover Street
Fitzroy, VIC 3065
Fitzroy, VIC 3065
CIK: 0001166272
ISIN: US37185R4065
CUSIP: 37185R208
